Menu

Recent Interviews

Humphrey Hale, CEO, Managing Geologist, Carnavale Resources Ltd.

Humphrey Hale
CEO, Managing Geologist | Carnavale Resources Ltd.
Level 2, Suite 9 389 Oxford Street, WA 6016 Mount Hawthorn (AUS)

info@carnavaleresources.com

Interview Carnavale Resources: Good cards for long-term success


Bill Guy, Chairman, Theta Gold Mines Limited

Bill Guy
Chairman | Theta Gold Mines Limited
Level 35 (ServCorp), Intl Tower One 100 Barangaroo Ave, 2000 NSW Australia (AUS)

info@thetagoldmines.com

+61 2 8046 7584

Interview Theta Gold Mines: This team has already brought 20 mines into production


David Mason, Managing Director, CEO, NewPeak Metals Ltd.

David Mason
Managing Director, CEO | NewPeak Metals Ltd.
Level 27, 111 Eagle Street, QLD 4000 Brisbane (AU)

info@newpeak.com.au

+61 7 3303 0650

Interview New Peak Metals: Many chances for great success


27. October 2020 | 10:17 CET

Pfizer, GlaxoSmithKline, EXMceuticals - Research in competition

  • Health
Photo credits: pixabay.com

By the end of 2020, the drug market is expected to more than double to USD 1.3 trillion, with the E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - accounting for about one-fifth of global drug sales. Also, the incidence of chronic diseases in developing countries will increasingly resemble that in industrialized countries. The evidence is abundant that the pharmaceutical industry business model is both economically unsustainable and operationally lethargic to produce the types of innovative treatments demanded by global markets. The industry must fundamentally change the way it operates to take full advantage of future growth opportunities. PwC's management consultants expect the industry to shift its focus from treatment to prevention. The traditional blockbuster sales model will disappear, and sophisticated direct sales channels will diminish the role of wholesalers. Let's take a closer look!

time to read: 3 minutes by André Will-Laudien
ISIN: CA30207T1049 , GB0009252882 , US7170811035


 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


Pfizer - Alzheimer on the map

The American pharmaceutical company Pfizer is known all over the world through Viagra! The research-based global biopharmaceutical Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes drugs, vaccines and preparations for the therapeutic areas of internal medicine, oncology, inflammation and immunology, rare diseases and consumer health care.

Its best-known brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra. It is now reported that the Company plans to address the issue of Alzheimer's disease together with IBM. The companies researchers developed an artificial intelligence-based voice data recognition system to predict whether a person is likely to develop Alzheimer's, according to a Thursday press release.

The underlying study examined spelling mistakes, the use of punctuation, repetition, object naming and memory in more extensive tests. Hopefully, a beneficial approach to early detection - even if a drug is still a long time coming. The Company has a market value of EUR 179 billion and announced the payment of the 328th quarterly dividend on December 1, 2020. Pfizer is an established name in the healthcare sector.

GlaxoSmithKline - weak on the chest for months

GlaxoSmithKline PLC (GSK) is a competitor of Pfizer, a global pharmaceutical company based in the UK. There is a lot of excitement this week as GSK will present its third-quarter 2020 results on October 28. In the last report, the Company delivered a negative earnings surprise; the share price subsequently fell by 20% to a downward trend.

The Company benefited by the reopening of international economies in May and recover from the disruption caused by COVID-19. In the third quarter, Glaxo's revenue growth is likely to have been driven by its booming pharmaceutical and self-medication segment. At the same time, vaccine sales are expected to remain weak. The whole world is waiting for a vaccine against COVID-19, and Glaxo as a pharmaceutical giant is not a frontrunner in the immune field like other specialized biotech companies.

In the meantime, the impact of Advair generics and increasing competition in the HIV segment may have affected sales. We are very excited, and the share has been under pressure since January despite a respectable dividend yield of 5.8%. The market capitalization is EUR 75 billion, which is less than half of Pfizer's. Perhaps this will also mark a turning point for the British - Brexit or not!

EXMceuticals - On the trail of the virus

EXMceuticals Inc. is a medical cannabis Company that firmly believes in the potential health and wellness applications of cannabis. EXM is an emerging player in this market with grand ambitions to become a significant producer of high-quality EU GMP cannabis and hemp ingredients. It is located near Lisbon, with a world-class extraction and refining facility dedicated to the production of cannabis material in Active Pharmaceutical Ingredients (API) quality.

EXM's ready-to-operate, equipped, licensed and staffed cannabis laboratory recently received a COVID-19 research and development grant from the European Union and the Portuguese government. This achievement represents a milestone for the Company. A consortium led by EXMceuticals Portugal Lda, operating under the project name "BioBlockCOVID" and consisting of EXMceuticals Portugal Lda, Cosmetek Lda and the Universiade de Coimbra, has received a grant of EUR 302,000 from the European Regional Development Fund and the Portuguese government. The funding will be used to investigate further and develop disinfectants to combat SARScoV-2, the virus that causes COVID-19.

EXMceuticals is in the final stage of detailed design for a standard pharmaceutical plant on an industrial scale in Portugal, which will complement the existing R&D laboratory and pilot refinery. In Setubal, south of Lisbon, a suitable plot of land has already been secured. Still, it needs to be converted to the API standards of the European Union. Upon completion, the plant will include extraction, purification and refining capacities as well as an R&D laboratory. The Company expects that the Setubal plant, when built, will be the largest cannabinoid and terpene processing facility in the European Union. One should take a closer look at the speculative value with a conceivably small capitalization of about CAD 14 million - because the low valuation calls potential buyers.


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

09. February 2021 | 08:00 CET | by Stefan Feulner

CureVac, Cardiol Therapeutics, Bayer - roaring profits!

  • Health

The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.

Read

08. February 2021 | 07:30 CET | by Nico Popp

Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here

  • Health

Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.

Read

28. January 2021 | 10:39 CET | by André Will-Laudien

Fresenius - Q&M Dental Group - IBU-tec: New price explosions every day!

  • Health

Rarely has the stock market been so volatile and exciting as in the last few days. Hedge fund Melvin Capital had to close out because of the GameStop share, and now the next wave is probably looming with AMC Entertainment. A full 270% went through the roof right at the opening; according to the New York Stock Exchange (NYSE) thousands of buy orders were already there at opening. Again, there had been a recommendation in a social media channel. On the Nasdaq, it jumped rapidly from USD 5 to USD 21 right at the opening - something you rarely see. And GameStop continues today after yesterday's debacle! After several trading suspensions, the value exploded further from USD 149 to USD 380 after a good hour of trading. That should have been the end of trading school for many new entrants!

Read